Trinity Biotech plans 1-for-30 reverse ADS split via ratio change

• Trinity Biotech plans to change its ADS ratio to 1 ADS for 600 Class A ordinary shares from 1 ADS for 20.
• The move equates to a 1-for-30 reverse ADS split, targeting Nasdaq’s $1 minimum bid rule.
• The ratio change is expected to take effect at the open on July 24, 2026, with the ticker remaining TRIB.
• No fractional new ADSs will be issued; fractional entitlements will be aggregated, sold, then paid out in cash net of costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220715PRIMZONEFULLFEED9766269) on July 22, 2026, and is solely responsible for the information contained therein.